Long non-coding RNA TINCR promotes hepatocellular carcinoma proliferation and invasion via STAT3 signaling by direct interacting with T-cell protein tyrosine phosphatase (TCPTP).
Hepatocellular carcinoma
RNA pull down
STAT3
TCPTP
TINCR
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
1
12
2021
Statut:
ppublish
Résumé
The long non-coding RNAs (lncRNAs) participate in modulating numerous important cancer phenotypes via formation of RNA-protein complex. TINCR (terminal differentiation-induced lncRNA) modulates cancer cell behavior in many human malignancies, such as hepatocellular carcinoma (HCC). Herein, we proposed to investigate the underlying mechanism by which TINCR regulates HCC progression via formation of RNA-protein. RNA pulldown, LC-MS/MS, bioinformatics analysis, and RNA immunoprecipitation (RIP) assays were employed to identify TINCR-interacting protein TCPTP in HCC cells. The siRNAs for TINCR and TCPTP were transfected into HCC cells. The plasmids encoding full length or the 1-360 nt deletion of TINCR were generated and applied to cell transfection. The CCK-8, colony formation, EdU, wound healing along with transwell assays were employed to examine cell proliferation, apoptosis, migration, and infiltration. Real-time PCR, as well as western blot assays were employed to assess the levels of STAT3 phosphorylation and its target genes. We identified 1-360 nt region of TINCR, which directly bound with the phosphatase domain of TCPTP to inhibit its tyrosine phosphatase activity. Then, the results showed that the increasing of cell growth, migration, infiltration, and the reducing of apoptosis in TINCR-knockdown HCC cells was remarkably reversed with TCPTP silence. Additionally, Δ1-360 TINCR overexpression did not affect HCC cell growth, apoptosis, migration, infiltration, and STAT3 target genes expression. Our data revealed that TINCR directly bound TCPTP and suppressed the dephosphorylation of STAT3, thus promoting STAT3 activation and its downstream target genes in HCC progression and tumorigenicity.HighlightsLncRNA TINCR interacted with protein TCPTPLncRNA TINCR maintained STAT3 phosphorylationLncRNA TINCR affected STAT3 signaling in HCCAbbreviations:lncRNAs: long non-coding RNAs; TINCR: terminal differentiation-induced lncRNA; TCPTP: T cell protein tyrosine phosphatase; siRNA: small-interfering RNA; HCC: hepatocellular carcinoma; nt: nucleotide; LC-MS/MS: Liquid Chromatography - Tandem Mass Spectrometry; RIP: RNA immunoprecipitation; ANOVA: analysis of variance; EdU: 5-ethynyl-2'-deoxyuridine; real-time PCR: real-time polymerase chain reaction; CCK-8: cell counting kit-8; aa: amino acids; STAT3: signal transducer and activator of transcription 3.
Identifiants
pubmed: 34057016
doi: 10.1080/21655979.2021.1930336
pmc: PMC8806792
doi:
Substances chimiques
RNA, Long Noncoding
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
TINCR lncRNA, human
0
PTPN2 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 2
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2119-2131Références
Nat Rev Cancer. 2014 Nov;14(11):736-46
pubmed: 25342631
Mol Cancer. 2019 Oct 25;18(1):147
pubmed: 31651347
BMC Med Genet. 2020 Jan 3;21(1):2
pubmed: 31900116
Biochem Biophys Res Commun. 2019 Feb 19;509(4):903-910
pubmed: 30642630
Hepatology. 2018 Jan;67(1):171-187
pubmed: 28746790
Biochem Biophys Res Commun. 2002 Oct 4;297(4):811-7
pubmed: 12359225
Bioengineered. 2020 Dec;11(1):1016-1026
pubmed: 32970959
Cancer Res. 2020 Dec 1;80(23):5174-5188
pubmed: 33067266
Cell Death Dis. 2017 Jun 1;8(6):e2837
pubmed: 28569791
Nat Rev Cancer. 2019 Feb;19(2):82-96
pubmed: 30578415
Cell. 2018 Nov 15;175(5):1289-1306.e20
pubmed: 30454647
Nature. 2013 Jan 10;493(7431):231-5
pubmed: 23201690
Mol Pharmacol. 2019 Aug;96(2):297-306
pubmed: 31221825
J Cell Biochem. 2019 Aug;120(8):13893-13902
pubmed: 30993776
Onco Targets Ther. 2017 Jul 10;10:3353-3362
pubmed: 28744139
J Hepatol. 2017 Sep;67(3):603-618
pubmed: 28438689
Pharmacol Ther. 2016 Jun;162:86-97
pubmed: 26478441
Biochem Biophys Res Commun. 2018 Mar 18;497(4):971-977
pubmed: 29427662
Pathol Res Pract. 2019 Oct;215(10):152596
pubmed: 31447059
Mol Cancer. 2019 Jan 8;18(1):3
pubmed: 30621694
Oncogene. 2015 Nov 5;34(45):5648-61
pubmed: 25728677
Bioengineered. 2021 Dec;12(1):578-588
pubmed: 33517826
Biosci Rep. 2017 Jul 27;37(4):
pubmed: 28546230
Nucleic Acids Res. 2003 Jul 1;31(13):3406-15
pubmed: 12824337
Hum Cell. 2019 Oct;32(4):515-521
pubmed: 31388923
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Oncogene. 2017 Oct 12;36(41):5661-5667
pubmed: 28604750
Aging (Albany NY). 2019 Mar 10;11(5):1389-1403
pubmed: 30853664
Cancer Manag Res. 2018 Aug 20;10:2799-2807
pubmed: 30154672
Nat Rev Gastroenterol Hepatol. 2018 Mar;15(3):137-151
pubmed: 29317776
EMBO J. 2012 Feb 1;31(3):522-33
pubmed: 22193719
Cancer Res. 2017 Aug 1;77(15):3965-3981
pubmed: 28701486
Cell Res. 2011 Jan;21(1):159-68
pubmed: 21187858
Mol Cell. 2014 Mar 6;53(5):752-65
pubmed: 24530303
Biomed Pharmacother. 2018 Mar;99:9-17
pubmed: 29324317
J Cell Physiol. 2020 Oct;235(10):6990-7002
pubmed: 31994189
J Hepatol. 2016 Jun;64(6):1283-94
pubmed: 26812074
Nucleic Acids Res. 2017 Sep 29;45(17):9947-9959
pubmed: 28973437
Bioinformatics. 2013 Nov 15;29(22):2928-30
pubmed: 23975767
Cancer Cell. 2016 Apr 11;29(4):452-463
pubmed: 27070700